Q-omics provides the consensus-scored ZNF879 profile across patient tissues and cancer cell-line models. ZNF879 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF879 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ZNF879 RNA expression shows 20,112 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where ZNF879 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF879 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF879 survival associations across molecular data types. ZNF879 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF879 RNA expression–survival associations across cancer types. High ZNF879 expression shows favorable associations in KIRC, MESO, LUAD, PAAD, ACC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF879 RNA expression.
This table summarizes ZNF879 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF879. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF879 shows lower tumor expression in KICH, HNSC, THCA, UCEC and COAD and higher tumor expression in CHOL. The KICH box plot shows higher ZNF879 RNA expression in normal versus tumor tissue (log2 FC = −1.561, t-test p < 0.001).
This table shows molecular features associated with ZNF879 in patient tissues and cancer cell lines. In patient samples, ZNF879 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF879 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
